CORDIS · TransBioNet
Accelerating Biomedical Translation through a European Network of Knowledge Valorisation Intermediaries
- Code
TransBioNet- Programme
- HORIZON
- Call
- VALLEYS Open Call #1
HORIZON-WIDERA-2025-06-ERA-01 - Status
- SIGNED
- Period
- 2026-09-01 – 2029-08-31
Official data · CORDIS · synced 2026-10-17 10:16 · official record
Participants
| Organisations | Role | Country | Grant |
|---|---|---|---|
| Associação Accelbio | coordinator | PT | 586 000 € |
| EATRIS ERIC | participant | NL | 342 500 € |
| EIT HEALTH INNOSTARS EV | participant | DE | 279 000 € |
| FORENINGEN DANISH LIFE SCIENCE CLUSTER | participant | DK | 229 312 € |
| BIOTEHNOLOGICHEN I ZDRAVEN KLASTER | participant | BG | 187 875 € |
| ASOCIACIJA LITHUANIABIO | participant | LT | 173 250 € |
| BIOCANT PARK, S.A. | participant | PT | 166 438 € |
Description
TransBioNet will establish the first pan-European network of knowledge valorisation intermediaries fully dedicated to drug discovery and biomedical innovation. Despite Europe’s world-class science, promising discoveries often fail to reach patients due to fragmented support, under-recognised intermediaries, and limited cross-border collaborations. TransBioNet addresses this gap by connecting regional clusters, pan-European infrastructures, and accelerators into a coherent ecosystem that equips intermediaries with harmonised tools, training, and services. The project will deliver three flagship resources: (i) the TransBioNet Digital Platform, a central hub integrating the Infrastructure Atlas, matchmaking tools, and training modules; (ii) a Valorisation Assessment Toolkit, providing standardised TRL/IRL evaluations embedding regulatory, IP, and market dimensions; and (iii) the TransBioNet Charter, a policy framework to ensure recognition of intermediaries across EU and national innovation strategies. Two Open Calls will support 12 early-stage drug discovery projects with mentoring, bootcamps, and access to infrastructures, creating tangible case studies of valorisation in practice. Through training programmes, secondments, and a Community of Practice, the project will build a new generation of skilled intermediaries able to de-risk biomedical projects, improve reproducibility, and accelerate translation. By lowering attrition rates and increasing investment readiness, TransBioNet will strengthen Europe’s competitiveness in drug discovery while ensuring inclusive participation of less-resourced regions. The project directly advances ERA Action 7 on Knowledge Valorisation, reinforcing open science, responsible research assessment, and cross-border collaboration. By its conclusion, TransBioNet will deliver a recognised European reference point for biomedical valorisation, ensuring that high-quality science translates into innovative therapies, jobs & societal impact.
Official data · CORDIS · synced 2026-10-17 10:16 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).